StockNews.AI
IBRX
StockNews.AI
173 days

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

1. IBRX received FDA's RMAT designation for innovative cancer therapies. 2. This milestone could enhance IBRX's market position in oncology.

2m saved
Insight
Article

FAQ

Why Bullish?

The FDA's RMAT designation typically leads to accelerated development and commercialization. Historical examples show similar designations have positively influenced stock prices in the biotech sector.

How important is it?

The FDA designation is a significant milestone that could attract investor interest and positively impact IBRX's stock price. Such advancements can lead to faster market entry, increasing the company's valuation.

Why Long Term?

Regulatory designations can take time to translate into market benefits. If successful, therapies can substantially increase IBRX’s revenues long-term.

Related Companies

VRTXAMGNREGN
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ANKTIVA® and CAR-NK (PD-L1 t-haNK) for the reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer. The complete blood count (CBC) is a standard assay wi.

Related News